BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

NCT00708214 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: BIBW 2992
DRUG: BIBW 2992
DRUG: Letrozole
DRUG: Letrozole

Sponsor

Boehringer Ingelheim